3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Conditions
Urinary Bladder Neoplasms
30
Carcinoma, Renal Cell
17
Prostatic Neoplasms
13
Carcinoma, Transitional Cell
11
Melanoma
8
Carcinoma, Non-Small-Cell Lung
7
Breast Neoplasms
7
Uterine Cervical Neoplasms
6
Kidney Neoplasms
6
Non-Muscle Invasive Bladder Neoplasms
5
Triple Negative Breast Neoplasms
4
Small Cell Lung Carcinoma
4
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Colorectal Neoplasms
4
Carcinoma, Merkel Cell
4
Squamous Cell Carcinoma of Head and Neck
3
Head and Neck Neoplasms
3
Carcinoma, Hepatocellular
3
Urothelial Cancer
2
Testicular Neoplasms
2
Stomach Neoplasms
2
Neoplasms
2
Lung Neoplasms
2
Hodgkin Disease
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Carcinoma in Situ
2
Carcinoma
2
Interventions
durvalumab
1
Observation
1
Gemcitabine
1
Cisplatin
1
Chemoradiotherapy
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gallbladder Cancer Unresectable
×
durvalumab
×
Genitourinary
×
Clear all
NCT06591650
2026-05-14
GCND
Fudan University
Phase 2
Recruiting
33 enrolled